Piperazine Derivatives
AssigneeM's Science Corporation
InventorsConnie L. Sun, Xiaoyuan Li
Life of this patent
Estimating the term…
Abstract
Compounds of general formula (I) in which R1, A1, A2 and R2 have any of the meanings given in the specification, have affinity for sigma receptors and are useful in the treatment of disorders of the central nervous system.
Claims31
1-15. (canceled)
A compound of general formula (I)
- in which:
- —
- R1 represents a phenyl group that is substituted by one or two fluorine atoms;
- A1 represents (CH2)m or (CH2)m-1C(═O);
- m is 2, 3, 4 or 5;
- A2 represents (CH2)n or C(═O)(CH2)n-1;
- n is 2, 3, 4 or 5;
- and
- R2 represents a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a cyano group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a halo(1-4C) alkyl group, a (1-4C)alkoxy group, a (1-4C)alkoxy(1-4C)alkoxy group, a hydroxy(1-4C)alkoxy group, a (1-4C)alkylsulfanyl group, a (1-4C)alkylsulfonyl group, a halo(1-4C)alkoxy group, and a halo(1-4C)alkylsulfonyl group;
- or a pharmaceutically acceptable salt thereof,
- or a stereoisomeric form or a polymorphic form of said compound or of said salt;
- provided that when A1 and A2 each represents (CH2)2, then R1 and R2 do not both represent 4-fluorophenyl.
A compound of general formula (I)
- in which:
- —
- R1 represents a phenyl group that is substituted by one or two fluorine atoms;
- A1 represents (CH2)m or (CH2)m-1C(═O);
- m is 2, 3, 4 or 5;
- A represents (CH2)n or C(═O)(CH2)n-1;
- n is 2, 3, 4 or 5;
- and
- R2 represents a phenyl group that is substituted by one or two substituents selected independently from a fluorine atom, a cyano group, a fluoro(1-4C) alkyl group, a (1-4C)alkylsulfonyl group, a fluoro(1-4C)alkoxy group and a fluoro(1-4C)alkylsulfonyl group;
- or a pharmaceutically acceptable salt thereof,
- or a stereoisomeric form or a polymorphic form of said compound or of said salt;
- provided that when A1 and A2 each represents (CH2)2, then R1 and R2 do not both represent 4-fluorophenyl.
A compound selected from the group consisting of:
- 1,4-Bis-[2-(2-fluorophenoxy)ethyl]piperazine dihydrochloride,
- 1,4-Bis-[3-(4-fluorophenoxy)propyl]piperazine,
- 1,4-Bis-[3-(2-fluorophenoxy)propyl]piperazine dihydrochloride,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-fluorophenoxy)propyl]piperazine dihydrochloride,
- and 2-(4-Fluorophenoxy)-1-{4-[2-(4-fluorophenoxy)acetyl]piperazin-1-yl}-ethanone,
- or a pharmaceutically acceptable salt of the selected compound, including a stereoisomeric form or a polymorphic form of said compound or of said salt.
A compound selected from the group consisting of:
- 4-(2-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
- 4-(2-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
- 4-(2-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
- 3-(2-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
- 3-(2-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
- 3-(2-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 4-(3-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 4-(3-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 4-(3-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 3-(3-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 3-(3-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 3-(3-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2-Difluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-methanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-methanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine, and
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- or a pharmaceutically acceptable salt of the selected compound, or a stereoisomeric form or a polymorphic form of said compound or of said salt.
A process for preparing a compound of the general formula (I)
- in which:
- —
- R1 represents a phenyl group that is substituted by one or two fluorine atoms;
- A1 represents (CH2)m or (CH2)m-1C(═O);
- m is 2, 3, 4 or 5;
- A represents (CH2)n or C(═O)(CH2)n-1;
- n is 2, 3, 4 or 5;
- and
- R1 represents a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a cyano group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a halo(1-4C) alkyl group, a (1-4C)alkoxy group, a (1-4C)alkoxy(1-4C)alkoxy group, a hydroxy(1-4C)alkoxy group, a (1-4C)alkylsulfanyl group, a (1-4C)alkylsulfonyl group, a halo(1-4C)alkoxy group, and a halo(1-4C)alkylsulfonyl group;
- or a pharmaceutically acceptable salt thereof,
- or a stereoisomeric form or a polymorphic form of said compound or of said salt;
- provided that when A1 and A2 each represents (CH2)2, then R1 and R2 do not both represent 4-fluorophenyl,
- comprising a process selected from the group consisting of:
- a) reacting a compound of general formula (II)
- in which each of Z1 and Z2 independently represents a leaving atom or group, or a corresponding compound in which one or more substituents on R2 are protected, with a compound of general formula (III)
- R1—O-A1-NH2 (III);
- b) reacting a compound of general formula (IV)
- in which each of Z3 and Z4 independently represents a leaving atom or group, with a compound of general formula (V)
- H2N-A2-O—R2 (V)
- or a corresponding compound in which one or more substituents on R2 are protected;
- c) reacting a compound of general formula (VI)
- with a compound of general formula (VII)
- Z5-A2-O—R2 VII)
- in which Z5 represents a leaving atom or group;
- d) reacting a compound of formula (VIII)
- with a compound of general formula (IX)
- R1—O-A1-Z6 (IX)
- in which Z6 represents a leaving atom or group;
- and
- e) for a compound of formula (I) in which A1 represents (CH2)m and A2 represents (CH2)n, reducing a corresponding compound of formula (I) in which A1 represents (CH2)m-1C(═O) and/or A2 represents C(═O)(CH2)n-1;
- the selected process followed by removing any protecting group, and, optionally, forming a pharmaceutically acceptable salt.
A method of treating a condition responsive to a modulator of sigma receptor function in a patient requiring treatment, which comprises administering to said patient an effective amount of a compound of general formula (I)
- in which:
- —
- R1 represents a phenyl group that is substituted by one or two fluorine atoms;
- A1 represents (CH2)m or (CH2)m-1C(═O);
- m is 2, 3, 4 or 5;
- A represents (CH2)n or C(═O)(CH2)n-1;
- n is 2, 3, 4 or 5;
- and
- R2 represents a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a cyano group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a halo(1-4C) alkyl group, a (1-4C)alkoxy group, a (1-4C)alkoxy(1-4C)alkoxy group, a hydroxy(1-4C)alkoxy group, a (1-4C)alkylsulfanyl group, a (1-4C)alkylsulfonyl group, a halo(1-4C)alkoxy group and a halo(1-4C)alkylsulfonyl group;
- or a pharmaceutically acceptable salt thereof, or a stereoisomeric form or a polymorphic form of said compound or of said salt,
- provided that when A1 and A2 each represents (CH2)2, then R1 and R2 do not both represent 4-fluorophenyl.
A method of treating a condition responsive to a modulator of sigma receptor function in a patient requiring treatment, which comprises administering to said patient an effective amount of a compound of general formula (I)
- in which:
- —
- R1 represents a phenyl group that is substituted by one or two fluorine atoms;
- A1 represents (CH2)m or (CH2)m-1C(═O);
- m is 2, 3, 4 or 5;
- A represents (CH2)n or C(═O)(CH2)n-1;
- n is 2, 3, 4 or 5;
- and
- R2 represents a phenyl group that is substituted by one or two substituents selected independently from a fluorine atom, a cyano group, a fluoro(1-4C) alkyl group, a (1-4C)alkylsulfonyl group, a fluoro(1-4C)alkoxy group and a fluoro(1-4C)alkylsulfonyl group;
- or a pharmaceutically acceptable salt thereof,
- or a stereoisomeric form or a polymorphic form of said compound or of said salt;
- provided that when A1 and A2 each represents (CH2)2, then R1 and R2 do not both represent 4-fluorophenyl.
A method of treating a condition responsive to a modulator of sigma receptor function in a patient requiring treatment, which comprises administering to said patient an effective amount of a compound selected from the group consisting of:
- 1,4-Bis-[2-(2-fluorophenoxy)ethyl]piperazine dihydrochloride,
- 1,4-Bis-[3-(4-fluorophenoxy)propyl]piperazine,
- 1,4-Bis-[3-(2-fluorophenoxy)propyl]piperazine dihydrochloride,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-fluorophenoxy)propyl]piperazine dihydrochloride,
- and 2-(4-Fluorophenoxy)-1-{4-[2-(4-fluorophenoxy)acetyl]piperazin-1-yl}-ethanone,
- or a pharmaceutically acceptable salt of the selected compound,
- or a stereoisomeric form or a polymorphic form of said compound or of said salt.
A method of treating a condition responsive to a modulator of sigma receptor function in a patient requiring treatment, which comprises administering to said patient an effective amount of a compound selected from the group consisting of:
- 4-(2-{4-[2-(4-Fluorophenoxy)ethyl]-piperazin-1-yl}ethoxy)benzonitrile,
- 4-(2-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
- 4-(2-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
- 3-(2-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
- 3-(2-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
- 3-(2-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}ethoxy)benzonitrile,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-trifluoromethylphenoxy)ethyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-methanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(4-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[2-(3-trifluoromethanesulfonylphenoxy)ethyl]piperazine,
- 4-(3-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 4-(3-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 4-(3-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 3-(3-{4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 3-(3-{4-[2-(2-Fluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 3-(3-{4-[2-(2,4-Difluorophenoxy)ethyl]piperazin-1-yl}propoxy)benzonitrile,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethylphenoxy)propyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2-Difluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-methanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-methanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-methanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(4-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(4-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- 1-[2-(2-Fluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine, and
- 1-[2-(2,4-Difluorophenoxy)ethyl]-4-[3-(3-trifluoromethanesulfonylphenoxy)propyl]piperazine,
- or a pharmaceutically acceptable salt of the selected compound, or a stereoisomeric form,
- or a polymorphic form of said compound or of said salt.
Dependencies are inferred from the claim text.